NeuBase Therapeutics Inc (NAS:NBSE)
$ 0.378 -0.012499 (-3.2%) Market Cap: 1.42 Mil Enterprise Value: -5.82 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 20/100

NeuBase Therapeutics Inc at Jefferies Healthcare Conference Transcript

Jun 10, 2022 / 01:00PM GMT
Release Date Price: $20.4 (-3.77%)
Unidentified Participant

Hello, and welcome to the Jefferies 2022 Healthcare Conference. It's my great honor to introduce Todd Branning, CFO of NeuBase Therapeutics. Thank you so much.

Todd Branning
NeuBase Therapeutics, Inc. - CFO

Good morning, everyone, and thank you so much for hosting us today here at the conference. We're pleased to be here. I am subbing for our CEO today, Dietrich Stephan. He was unfortunately unavailable to make it this morning. So I'll be doing the presentation, but hopefully, we'll be able to cover all the details that Dietrich would have covered if he were here.

So I'll start out by saying that we acknowledge that NeuBase is -- it's difficult to get some attention on a company like NeuBase in this environment that we're in right now. We are a small preclinical company at this phase of our existence. But we accept that as our current reality and know that there are going to be companies like us that do, over time, generate what we believe will be successful performance, and we believe NeuBase will be one of the one of those companies.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot